FrancophonIA/ELRC3.0 huggingface dataset:
English: Because of the long half-life of cariprazine and its active metabolites, changes in dose will not be fully reflected in plasma for several weeks.
Slovenian: Zaradi dolge razpolovne dobe kariprazina in njegovih aktivnih presnovkov spremembe odmerka na koncentracijah v plazmi ne bodo v celoti vidne še nekaj tednov.
English: A 2-part study (a single dose of 1 mg cariprazine [Part A] and a daily dose of 0.5 mg cariprazine for 14 days [Part B] was conducted in patients with varying degrees of impaired hepatic function (ChildPugh Classes A and B).
Slovenian: 2-delno študijo (enkratni odmerek 1 mg kariprazina [del A] in dnevni odmerek 0,5 mg kariprazina v obdobju 14 dni [del B]) so izvedli pri bolnikih z različnimi stopnjami okvare jeter (razred A in B po Child-Pughu).
English: Talk to your doctor or pharmacist before taking Reagila, or during treatment if you have: - ever experienced or start to experience restlessness and inability to sit still.
Slovenian: Pred začetkom jemanja zdravila Reagila ali med zdravljenjem se posvetujte z zdravnikom ali farmacevtom, zlasti če: - ste kadar koli imeli ali začenjate opažati nemir in nesposobnost sedeti pri miru.
English: The plasma concentration of total cariprazine decreases by 50% in ~1 week and greater than 90% decline in total cariprazine concentration occurs in ~3 weeks.
Slovenian: Koncentracije skupnega kariprazina v plazmi se zmanjšajo za 50 % v ~ 1 tednu, po ~3 tednih pa je skupni upad koncentracije kariprazina več kot 90 %.
English: The mean terminal half-life (1 to 3 days for cariprazine and DCAR and 13 to 19 days for DDCAR) is not predictive of time to reach steady state or plasma concentration decline after treatment discontinuation.
Slovenian: S povprečno končno razpolovno dobo (1 do 3 dni za kariprazin in DCAR in 13 do 19 dni za DDCAR) ni možno napovedati časa do doseženega stanja dinamičnega ravnovesja ali upada koncentracije v plazmi po prekinitvi zdravljenja.
English: Women of childbearing potential must use highly effective contraception while taking cariprazine and at least for 10 weeks after stopping treatment (see sections 4.5 and 4.6).
Slovenian: Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem s kariprazinom in še vsaj 10 tednov po prenehanju zdravljenja (glejte poglavji 4.5 in 4.6).
English: Cariprazine has no appreciable affinity for cholinergic muscarinic receptors (IC50 > 1000 nM).
Slovenian: Kariprazin nima opazne afinitete za holinergične muskarinske receptorje (IC50 > 1.000 nM).
English: Cariprazine should be used with caution in patients with known cardiovascular disease predisposing to blood pressure changes.
Slovenian: Kariprazin je treba uporabljati previdno pri bolnikih z znanimi kardiovaskularnimi boleznimi, ki povečajo nagnjenost za spremembe krvnega tlaka.
English: Neonates exposed to antipsychotics (including cariprazine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery.
Slovenian: Pri novorojencih, izpostavljenih antipsihotikom (vključno s kariprazinom) v tretjem trimesečju nosečnosti, obstaja tveganje za neželene učinke, vključno z ekstrapiramidnimi in/ali odtegnitvenimi simptomi, ki se lahko po resnosti in trajanju po porodu razlikujejo.
English: Schizophrenia is a disease characterised by symptoms such as hearing, seeing or sensing things which are not there (hallucination), suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness.
Slovenian: Shizofrenija je bolezen, za katero so značilni simptomi, kot so slušne, vidne in čutne zaznave neobstoječih stvari (halucinacije), sumničavost, zmotna prepričanja, nepovezano govorjenje in vedenje ter čustvena praznost.
English: Differences on the Clinical Global Impression Severity (p=0.005) and Improvement (p<0.001) scales,
Slovenian: Razlike na lestvicah celokupnega kliničnega vtisa glede resnosti (Clinical Global Impression Severity) (p = 0,005) in izboljšanja (p < 0,001) in stopnja odgovora PANSS-FSNS (PANSS FSNS ≥ 30 %
English: Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure.
Slovenian: Dodatni znaki lahko vključujejo mioglobinurijo (rabdomiolizo) in akutno ledvično odpoved.
English: Akathisia and restlessness is a frequently occurring adverse reaction of antipsychotics.
Slovenian: Akatizija in nemir sta pogosta neželena učinka antipsihotikov.
English: Efficacy in predominantly negative symptoms of schizophrenia The efficacy of cariprazine for the treatment of predominantly negative symptoms of schizophrenia was investigated in a 26-week, multi-centre, double-blind, and active-controlled clinical trial.
Slovenian: Učinkovitost pri pretežno negativnih simptomih shizofrenije Učinkovitost kariprazina pri zdravljenju pretežno negativnih simptomov shizofrenije so preučili v 26-tedenskem, multicentričnem, dvojno slepem in z učinkovino nadzorovanem kliničnem preskušanju.
English: Women using systemically acting hormonal contraceptives should add a second barrier method.
Slovenian: Ženske, ki uporabljajo sistemsko delujoče hormonske contraceptive, morajo dodati še pregradno metodo.
English: Unchanged cariprazine is excreted by 1.2% of the dose in urine and 3.7% of the dose in feces.
Slovenian: Nespremenjenega kariprazina se izloči 1,2 % odmerka z urinom in 3,7 % odmerka z blatom.
English: - if you experience a combination of fever, sweating, faster breathing, muscle stiffness and drowsiness or sleepiness (may be signs of neuroleptic malignant syndrome).
Slovenian: - če se pojavi kombinacija zvišane telesne temperature, znojenja, hitrejšega dihanja, mišične togosti in dremavosti ali zaspanosti (to so lahko znaki nevroleptičnega malignega sindroma).
English: Adverse drug reactions occurring in patients with schizophrenia
Slovenian: Neželeni učinki zdravila, ki se pojavljajo pri bolnikih s shizofrenijo
English: Cariprazine is a P-gp inhibitor in vitro at its theoretical maximum intestinal concentration.
Slovenian: Kariprazin je zaviralec P-gp in vitro pri teoretični največji koncentraciji v prebavilih.
English: Cariprazine and its metabolites were excreted in milk of rats during lactation.
Slovenian: Kariprazin in njegovi presnovki so se izločali v mleko podgan med laktacijo.
English: In addition, pale, cold bodies and developmental delays (renal papillae not developed/underdeveloped and decreased auditory startle response in males) were observed in the absence of maternal toxicity.
Slovenian: Poleg tega so opazili bleda, hladna telesa in zaostanke v razvoju (nerazvita/premalo razvita ledvična papila in zmanjšanje reakcije na slušni dražljaj pri samcih) v odsotnosti toksičnosti za mater.
English: During the schizophrenia clinical development program of cariprazine, few cataract cases were reported, characterized with minor lens opacities with no visual impairment (13/3192; 0.4%).
Slovenian: Med kliničnim razvojnim programom kariprazina za zdravljenje shizofrenije so poročali o nekaj primerih katarakte, za katere je bila značilna manjša motnjava leče brez okvare vida (13/3192; 0,4 %).
English: Potential for cariprazine to affect other medicinal products
Slovenian: Možnost, da bi kariprazin vplival na druga zdravila
English: Common (≥1/100 to
Slovenian: Pogosti (≥ 1/100 do
English: No inflammation was observed at the end of 2-month drug-free period at an exposure 4.2 times the clinical exposure at the MRHD; however, inflammation was still present at higher doses.
Slovenian: Ob koncu 2-mesečnega obdobja brez zdravila niso opazili vnetja ob izpostavljenosti, ki je bila 4,2-kratnik klinične izpostavljenosti pri MRHD; vendar je bilo pri večjih odmerkih vnetje še vedno prisotno.
English: Richter Gedeon Nyrt.
Slovenian: Magyarország Richter Gedeon Nyrt.
English: In female rats, lower fertility and conception indices were observed at clinically relevant exposures based on mg/m2 body surface area.
Slovenian: Pri podganjih samicah so opazili nižje indekse plodnosti in zanositve pri klinično pomembnih izpostavljenostih na podlagi mg/m2 telesne površine.
English: Printing ink (black: 1.5 mg, 3 mg and 6 mg capsules)
Slovenian: Črnilo (črno: 1,5 mg, 3 mg in 6 mg kapsule)
English: The dose can be modified based on individual response and tolerability (see section 4.8).
Slovenian: Odmerek se lahko prilagodi glede na odziv in prenašanje zdravila pri posamezniku (glejte poglavje 4.8).
English: This suggests that an interaction of cariprazine with inhibitors of P-gp, OATP1B1, OATP1B3 and BCRP is unlikely.
Slovenian: To kaže, da interakcija kariprazina z zaviralci P-gp, OATP1B1, OATP1B3 in BCRP ni verjetna.
English: PANSS-FSNS at Baseline PANSS-FSNS at Week 26 PANSS-FSNS CfB to Week 26
Slovenian: PANSS-FSNS ob izhodišču PANSS -FSNS v 26. tednu
English: The plasma concentration of total cariprazine will gradually decline following dose discontinuation or interruption.
Slovenian: Skupne koncentracije kariprazina v plazmi po prenehanju ali prekinitvi odmerjanja upadajo postopoma.
English: In rabbits, cariprazine caused maternal toxicity, but no foetal toxicity at exposures 5.8 times the clinical exposure at the MRHD.
Slovenian: Pri kuncih je kariprazin povzročil toksičnost za mater, vendar ni bilo toksičnosti za plod pri izpostavljenosti 5,8-kratnika klinične izpostavljenosti pri MRHD.
English: Following administration of 12.5 mg/day cariprazine to patients with schizophrenia, 20.8% of the dose was excreted in urine as cariprazine and its metabolites.
Slovenian: Po dajanju kariprazina v odmerku 12,5 mg/dan bolnikom s shizofrenijo se 20,8 % odmerka izloči z urinom v obliki kariprazina in njegovih presnovkov.
English: No patients treated with cariprazine experienced QTc increases ≥ 60 msec from baseline, nor did any patient experience a QTc of > 500 msec in the study.
Slovenian: Noben bolnik, zdravljen s kariprazinom, ni imel povečanja QTc ≥ 60 msek od izhodišča, in noben bolnik v študiji ni imel QTc > 500 msek.
English: Due to the long half-life of the active moieties of cariprazine a further increase in plasma exposure of total cariprazine can be expected during longer co-administration.
Slovenian: Zaradi dolge razpolovne dobe aktivnih sestavin kariprazina se lahko pri daljšem sočasnem dajanju pričakuje nadaljnje povečanje izpostavljenosti skupnemu kariprazinu v plazmi.
English: QT- prolongation
Slovenian: Podaljšanje intervala QT
English: SPECIAL STORAGE CONDITIONS Keep the blister in the outer carton in order to protect from light.
Slovenian: POSEBNA NAVODILA ZA SHRANJEVANJE Pretisni omot shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
English: Administration of a single dose of 1.5 mg cariprazine with a high-fat meal (900 to 1,000 calories) did not significantly affect the Cmax or AUC of cariprazine (AUC0-∞ increased by 12%, Cmax decreased by < 5% under fed condition versus fasting).
Slovenian: Enkratno dajanje odmerka 1,5 mg kariprazina z obrokom, bogatim z maščobami (900 do 1.000 kalorij) ni pomembno vplivalo na Cmax ali AUC kariprazina (AUC0-∞ se je povečal za 12 %, Cmax se je zmanjšal za < 5 % v pogojih s hrano v primerjavi s stanjem na tešče).
English: Following multiple-dose administration, peak plasma concentrations for cariprazine and the major active metabolites generally occur at approximately 3-8 hours post dose.
Slovenian: Po večkratnem dajanju odmerkov se največje koncentracije kariprazina in glavnih aktivnih presnovkov v plazmi običajno pojavijo približno 3 do 8 ur po odmerku.
English: The capsules are packed in transparent hard PVC/PE/PVDC blister heat-sealed with hard aluminium foil backing.
Slovenian: Kapsule so pakirane v prozorne trde pretisne omote iz PVC/PE/PVDC, toplotno zavarjene s trdo aluminijasto folijo na hrbtni strani.
English: If you are using hormonal contraceptives a so-called barrier method should also be used (see section “Pregnancy and breast-feeding” below).
Slovenian: Če uporabljate hormonske kontraceptive, morate uporabljati tudi tako imenovano pregradno metodo (glejte spodnje poglavje „Nosečnost in dojenje“).
English: An additional metabolite, desdichlorophenyl piperazine cariprazine (DDCPPCAR) acid, is produced by dealkylation and subsequent oxidation of cariprazine.
Slovenian: Dodatni presnovek, dezdiklorofenil piperazin kariprazinska kislina (DDCPPCAR), nastane z dealkilacijo in sledečo oksidacijo kariprazina.
English: Cariprazine caused bilateral cataract and secondary retinal changes (retinal detachment and cystic degeneration) in the dog.
Slovenian: Kariprazin je pri psih povzročil obojestransko katarakto in sekundarne mrežnične spremembe (odstop mrežnice in cistično degeneracijo).
English: Population pharmacokinetic modelling was performed using data from patients enrolled in the schizophrenia cariprazine clinical program with differing levels of renal function, including normal renal function (creatinine clearance (CrCl) ≥ 90 mL/min), as well as mild (CrCl 60 to 89 mL/min) and moderate (CrCl 30 to 59 mL/min) renal impairment.
Slovenian: Modeliranje populacijske farmakokinetike so izvedli s podatki bolnikov, vključenih v klinični program kariprazina za zdravljenje shizofrenije, z različnimi ravnmi okvare ledvic, vključno z normalnim delovanjem ledvic (očistek kreatinina (CrCl, creatinine clearance) ≥ 90 ml/min), in blago (CrCl 60 do 89 ml/min) ter zmerno (CrCl 30 do 59 ml/min) okvaro ledvic.
English: (Rare side effect) - combination of fever, sweating, muscle stiffness, and drowsiness or sleepiness.
Slovenian: (Redek neželeni učinek) - kombinacija zvišane telesne temperature, znojenja, mišične togosti in dremavost ali zaspanost.
English: The most frequently reported ADRs with cariprazine in the dose range (1.5-6 mg) were akathisia (19%) and parkinsonism (17.5%).
Slovenian: Najpogosteje poročana neželena učinka s kariprazinom v celotnem razponu odmerkov (1,5-6 mg) sta bila akatizija (19 %) in parkinsonizem (17,5 %).
English: Total cariprazine (sum of cariprazine + DCAR and DDCAR) exposure approaches 50% of steady state exposure in ~1 week of daily dosing while 90% of steady state is achieved in 3 weeks.
Slovenian: Skupna izpostavljenost kariprazinu (vsota kariprazin + DCAR in DDCAR) se približa 50 % vrednosti izpostavljenosti v stanju dinamičnega ravnovesja po ~1 tednu dnevnega odmerjanja, medtem ko je 90 % stanja dinamičnega ravnovesja doseženo v 3 tednih.
English: Cariprazine (dose range 3-6 mg, target dose 4.5 mg) was investigated compared to risperidone (dose range 3-6 mg, target dose 4 mg) in patients with persistent, predominant negative symptoms of schizophrenia (n=461).
Slovenian: Kariprazin (razpon odmerka od 3 do 6 mg, ciljni odmerek 4,5 mg) so preučili v primerjavi z risperidonom (razpon odmerka od 3 do 6 mg, ciljni odmerek 4 mg) pri bolnikih z vztrajnimi, pretežno negativnimi simptomi shizofrenije (n = 461).
English: It is currently unknown whether cariprazine may reduce the effectiveness of systemically acting hormonal contraceptives, and therefore women using systemically acting hormonal contraceptives should add a second barrier method.
Slovenian: Trenutno ni znano, ali lahko kariprazin zmanjša učinkovitost sistemsko delujočih hormonskih kontraceptivov, zato morajo ženske, ki uporabljajo sistemsko delujoče hormonske kontraceptive, uporabljati še drugo, pregradno metodo.
English: You may experience dizziness from low blood pressure, or have abnormal heartbeats, you may feel sleepy, tired, or have abnormal body movements and find it difficult to stand or walk.
Slovenian: Morda boste omotični zaradi nizkega krvnega tlaka, imeli nenormalni srčni utrip, boste zaspani, utrujeni ali pa boste imeli nenormalne telesne gibe in težave pri stanju ali hoji.
English: Taking Reagila together with some medicines may require a dose adjustment of Reagila or the other medicine.
Slovenian: Če jemljete zdravilo Reagila skupaj z nekaterimi drugimi zdravili, bo morda treba prilagoditi odmerek zdravila Reagila ali drugega zdravila.
English: It is currently unknown if cariprazine may reduce the effectiveness of systemically acting hormonal contraceptives and therefore women using systemically acting hormonal contraceptives should add a barrier method (see section 4.5).
Slovenian: Trenutno ni znano, ali lahko kariprazin zmanjša učinkovitost sistemsko delujočih hormonskih kontraceptivov, zato morajo ženske, ki uporabljajo sistemsko delujoče hormonske contraceptive, uporabljati še drugo, pregradno metodo (glejte poglavje 4.5).
English: Administration of cariprazine to rats during the period of organogenesis caused malformations, lower pup survival, and developmental delays at drug exposures less than the human exposure at the MRHD of 6 mg/day.
Slovenian: Dajanje kariprazina podganam v obdobju organogeneze je povzročilo malformacije, manjše preživetje mladičev in zaostanek v razvoju pri izpostavljenosti zdravilu, ki je bila nižja od izpostavljenosti pri ljudeh z MRHD 6 mg/dan.
English: Akathisia is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion, as well as by actions such as rocking while standing or sitting, lifting the feet as if marching on the spot, and crossing and uncrossing the legs while sitting.
Slovenian: Akatizija je motnja gibanja, za katero sta značilna občutek notranjega nemira in nujna potreba po stalnem gibanju pa tudi gibi, kot so zibanje med stanjem ali sedenjem, dviganje stopal kot pri korakanju na mestu in prekrižanje ter odkrižanje nog med sedenjem.
English: The metabolism of cariprazine involves demethylation (DCAR and DDCAR), hydroxylation (hydroxy cariprazine, HCAR) and a combination of demethylation and hydroxylation (hydroxy desmethyl cariprazine, HDCAR and hydroxy didesmethyl cariprazine, HDDCAR).
Slovenian: Presnova kariprazina vključuje demetilacijo (DCAR in DDCAR), hidroksilacijo (hidroksi-kariprazin, HCAR) in kombinacijo demetilacije in hidroksilacije (hidroksi-desmetil kariprazin, HDCAR in hidroksi-didesmetil kariprazin, HDDCAR).
English: In the open-label phase of the study during 20 weeks cariprazine treatment 9.0% of patients developed potentially clinically significant (PCS) weight gain (defined as increase ≥ 7%) while during the double-blind phase, 9.8 % of the patients who continued with cariprazine treatment had PCS weight gain versus 7.1% of the patients who were randomized to placebo after the 20 week open-label cariprazine treatment.
Slovenian: V odprti fazi študije so med 20 tedni zdravljenja s kariprazinom pri 9,0 % bolnikov poročali o potencialno klinično pomembnem zvečanju telesne mase (opredeljenem kot zvečanje ≥ 7 %), medtem ko so po 20 tednih odprtega zdravljenja s kariprazinom med dvojno slepo fazo zabeležili potencialno klinično pomembno zvečanje telesne mase pri 9,8 % bolnikov, ki so nadaljevali zdravljenje s kariprazinom, v primerjavi s 7,1 % bolnikov, randomiziranih na placebo.
English: Cariprazine and its major active metabolites did not induce CYP1A2, CYP2B6 and CYP3A4 enzymes and were not inhibitors of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP219, CYP2D6, CYP2E1 and CYP3A4 in vitro.
Slovenian: Kariprazin in njegova glavna aktivna presnovka in vitro niso inducirali encimov CYP1A2, CYP2B6 ter CYP3A4 in niso bili zaviralci CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP219, CYP2D6, CYP2E1 in CYP3A4.
English: Safety and efficacy of cariprazine have not been evaluated in patients with severe renal impairment (CrCl < 30 mL/min).
Slovenian: Varnost in učinkovitost kariprazina nista bili ocenjeni pri bolnikih s hudo okvaro ledvic (CrCl < 30 ml/min).
English: The recommended starting dose is 1.5 mg once a day by mouth.
Slovenian: Priporočeni začetni odmerek je 1,5 mg enkrat na dan peroralno.
English: Change From Baseline to Week 6 in the PANSS Total Score in Studies of Acute Exacerbations of Schizophrenia-ITT Population
Slovenian: Sprememba od izhodišča do 6. tedna v skupni vrednosti PANSS v študijah akutne eksacerbacije shizofrenije pri populaciji ITT Izhodišče povprečje
English: Absolute bioavailability of cariprazine is unknown.
Slovenian: Absolutna biološka uporabnost kariprazina ni znana.
English: CYP2D6 mediated pathway plays a minor role in the metabolism of cariprazine, the major pathway is via CYP3A4 (see section 5.2).
Slovenian: Pot, pri kateri posreduje CYP2D6, ima manjšo vlogo pri presnovi kariprazina, glavna pot poteka prek CYP3A4 (glejte poglavje 5.2).
English: (Uncommon side effect)
Slovenian: (Občasen neželeni učinek)
English: If you were taking another medicine to treat schizophrenia before starting Reagila, your doctor will decide whether to stop the other medicine gradually or immediately and how to adjust the dose of Reagila.
Slovenian: Če ste pred jemanjem zdravila Reagila jemali drugo zdravilo za zdravljenje shizofrenije, se bo zdravnik odločil, ali boste z jemanjem prejšnjega antipsihotika prenehali postopoma ali takoj, in ali je potrebna prilagoditev odmerka kariprazina.
English: Side effects with not known frequency (frequency cannot be estimated from the available data) - inflammation of the liver (pain in the upper right abdomen, yellowing of the eye and skin,
Slovenian: Neželeni učinki z neznano pogostnostjo (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) - vnetje jeter (bolečine v spodnjem delu trebuha, porumenelost oči in kože, šibkost, zvišana telesna temperatura)
English: Hypertrophy of the adrenal gland cortex was observed at 4.1 times the clinical exposure at the MRHD in rats (females only) and at clinically relevant total cariprazine plasma concentrations in mice.
Slovenian: Hipertrofijo korteksa nadledvične žleze so opazili pri 4,1-kratniku kliničnega odmerka MRHD pri podganah (le samice) in pri klinično pomembnih skupnih koncentracijah kariprazina v plazmi pri miših.
English: The capsules are filled with white to yellowish white powder.
Slovenian: Kapsule so napolnjene z belim do rumenkasto belim praškom.
English: However the therapeutic effect of cariprazine may be mediated through a combination of partial agonist activity at dopamine D3, D2 (Ki values of 0.085-0.3 nM versus 0.49-0.71 nM respectively) and serotonin 5-HT1A receptors (Ki values of 1.4-2.6 nM), and antagonist activity at serotonin 5-HT2B, 5-HT2A and histamine H1 receptors (Ki values of 0.58-1.1 nM, 18.8 nM and 23.3 nM, respectively).
Slovenian: Vendar pa je lahko terapevtski učinek kariprazina posledica kombinacije delnega agonističnega učinka na receptorje dopamina D3, D2 (vrednosti Ki 0,085 do 0,3 nM v primerjavi z 0,49 do 0,71 nM) in serotoninske receptorje 5HT1A (vrednosti Ki 1,4 do 2,6 nM) ter antagonističnega učinka na serotoninske receptorje 5HT2B, 5HT2A in histaminske receptorje H1 (vrednosti Ki 0,58 do 1,1 nM, 18,8 nM in 23,3 nM).
English: Administration of cariprazine to pregnant rats during the period of organogenesis, throughout pregnancy and lactation at clinically relevant exposures decreased postnatal survival, birth weight, and post-weaning body weight of first generation pups.
Slovenian: Dajanje kariprazina brejim podganam v obdobju organogeneze, v času brejosti in laktacije v klinično pomembnih izpostavljenostih je pri prvi generaciji mladičev zmanjšalo preživetje po porodu, telesno maso ob porodu in telesno maso po odstavitvi.
English: Alcohol should be avoided when taking Reagila.
Slovenian: Med jemanjem zdravila Reagila se je treba izogibati alkoholu.
English: In the placebo-controlled part of the long-term maintenance of effect study EPS was 13.7% in the cariprazine group compared to 3.0% in the placebo treated patients.
Slovenian: V s placebom nadzorovanem delu dolgoročne študije vzdrževanja učinkovitosti so EPS opazili pri 13,7 % bolnikov v skupini s kariprazinom v primerjavi s 3,0 % v skupini s placebom.
English: Gastrooesopha geal reflux disease
Slovenian: bruhanje gastroezofagealna refluksna bolezen disfagija
English: Ketoconazole, a strong CYP3A4 inhibitor, caused two fold increase in plasma exposure for total cariprazine (sum of cariprazine and its active metabolites) during short-term (4 days) co-administration, either if unbound or unbound+bound moieties considered.
Slovenian: Ketokonazol, močan zaviralec CYP3A4, je pri kratkotrajnem sočasnem dajanju (4 dni) povzročil dvakratno povečanje izpostavljenosti skupnemu kariprazinu v plazmi (vsota kariprazina in njegovih aktivnih presnovkov), bodisi če se gleda nevezano ali nevezano + vezano učinkovino.